Racism and implicit bias in healthcare systems continue to have negative effects on the patient experience and treatment outcomes of Black women.
Genentech, a member of the Roche Group announced results from the Phase IV CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial evaluating Ocrevus (ocrelizumab) in Black and Hispanic / Latinx people with relapsing multiple sclerosis (MS)
Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta
Learn more about key highlights in dermatology, focusing on alopecia areata from the American Academy of Dermatology 2023 Annual Meeting.
After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches.
Eliem Therapeutics, Inc.and Tenet Medicines, Inc. a development-stage private biotechnology company, announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.
Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure. (heart failure with preserved ejection fraction)
The primary objective of the study is to assess the anti-lymphoma activity of glofitamab, a bispecific CD3xCD20 monoclonal antibody in patients with relapse/refractory DLBCL (cohort 1) disease after anti-CD19 CAR T-cells therapy